Theranos: When Elite Board Partnerships Enable a $9 Billion Fraud

The Most Dangerous Board Table in Silicon Valley

By 2015, Theranos had assembled a board that read like a who's who of American institutional power. George Shultz. Henry Kissinger. James Mattis. William Perry. Two former US senators. A former CDC director. A former Navy admiral.

No one on that board had a background in medicine, diagnostics, laboratory science, or biotech.

That was not an accident. It was the architecture of the fraud.

Elizabeth Holmes understood something that very few founders — and almost no scammers — grasp at that level of sophistication: in high-stakes business, the quality of your partners signals the quality of your product. She didn't need her technology to work. She needed her partnerships to make people believe it worked.

For nearly a decade, they did.

What Theranos Actually Promised

Theranos claimed to have developed a revolutionary blood-testing device called the Edison that could run hundreds of diagnostic tests from a single finger-prick of blood — faster, cheaper, and more accurately than conventional lab equipment.

If true, it would have been one of the most significant medical breakthroughs in decades. The implications for global healthcare access were staggering. Holmes pitched it with missionary intensity, comparing herself to Steve Jobs and positioning the company as a technology startup rather than a medical device company — a distinction that would later prove critical, since medical device companies face FDA scrutiny while tech startups don't.

Walgreens partnered with Theranos to offer the tests in its pharmacy chain. Safeway invested $350 million to install Theranos clinics in its stores. The US Department of Defense was approached about deploying the technology in battlefield conditions.

The company was valued at $9 billion. Holmes herself was worth $4.5 billion on paper. She was on the covers of Forbes, Fortune, and Time.

None of it was real.

The Partnership Strategy That Made the Fraud Possible

The Edison device couldn't reliably do what Holmes claimed. Internally, Theranos ran most of its tests on commercially available Siemens machines while presenting results as if they came from the Edison. The tests that were run on the Edison produced wildly inaccurate results — results that were delivered to real patients making real medical decisions.

So how did Theranos survive for so long?

Because Holmes had built an architecture of credibility through partnerships that made scrutiny feel unnecessary — and in some cases, actively dangerous to engage in.

The board wasn't advisory. It was armor. When journalists or potential investors questioned the technology, they were implicitly questioning the judgment of Henry Kissinger and two former secretaries of state. The social cost of skepticism was engineered to be higher than the social cost of belief.

Strategic partners became unwitting validators. Walgreens's investment gave Theranos mainstream retail legitimacy. Safeway's $350 million investment gave it financial credibility. Neither company had independently verified the technology before committing. They were each relying on the other's due diligence — which neither had actually done.

Secrecy was reframed as IP protection. Holmes refused to allow peer review or independent testing of the Edison, citing competitive concerns. In any other context, this would be a massive red flag. In the context of her partner roster and funding rounds, it was treated as the reasonable caution of a visionary protecting trade secrets.

The Whistleblowers Nobody Listened To

Tyler Shultz — grandson of board member George Shultz — joined Theranos as a young engineer and quickly realized the technology didn't work as advertised. He reported his concerns internally and was threatened with legal action. He eventually went to the California Department of Public Health and then to Wall Street Journal reporter John Carreyrou.

His grandfather, one of Theranos's most prominent partners, sided with Holmes over his own family member. The social gravity of the partnership web was strong enough to override a direct personal warning.

Erika Cheung, another young employee, also raised internal concerns and faced similar retaliation before eventually cooperating with regulators.

Both whistleblowers faced years of legal threats from Theranos before the fraud was exposed.

The Collapse

John Carreyrou's October 2015 Wall Street Journal investigation began unraveling the story. The Centers for Medicare and Medicaid Services found deficiencies so serious they threatened the lab's federal certification. Walgreens and Safeway severed ties. The DOD partnership never materialized.

Holmes was charged with federal fraud and conspiracy in 2018. In January 2022, she was convicted on four counts of fraud and conspiracy against investors. She was sentenced to more than 11 years in prison. Her former partner and COO Ramesh "Sunny" Balwani received a nearly 13-year sentence.

Patients who received inaccurate Theranos test results — tests that influenced real medical decisions about cancer, HIV, medication dosing, and pregnancy — were notified years after the fact.

The Partnership Lessons That Outlast the Headlines

Theranos is not primarily a story about technology fraud. It's a story about how partnership credibility can be weaponized.

Prestigious names are not due diligence. The presence of decorated partners signals social proof, not technical validation. The board members at Theranos were there for their networks and their credibility, not their ability to evaluate blood-testing equipment.

Institutional partners rely on each other's diligence — and often no one actually does it. Walgreens assumed Safeway had vetted the technology. Safeway assumed the board had. The board assumed Holmes's secrecy was justified. In complex multi-party partnerships, this circular trust is one of the most common mechanisms for large-scale fraud to survive.

Emotional narrative overrides analytical scrutiny. Holmes's story — a young woman disrupting a male-dominated industry, democratizing healthcare, saving lives — was so compelling that critical questions felt callous. Scammers at scale are almost always selling a story more than a product.

Secrecy in partnerships should always require justification. Any partner who cannot or will not allow independent verification of their core value proposition deserves aggressive skepticism regardless of who else is in the room with them.

The technology that Theranos claimed to be building was theoretically possible. The fraud was in the gap between what was claimed and what existed — and partnerships were the bridge that kept that gap hidden long enough to steal $900 million from investors and endanger the health of thousands of patients.